Wire · opportunities
Belzutifan Plus Lenvatinib Approved for Advanced ccRCC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
The FDA approved the combination of belzutifan (Merck) and lenvatinib (Eisai) for adults with advanced clear cell renal cell carcinoma (ccRCC) who have progressed following PD-1 or PD-L1 inhibitor therapy, marking the third indication for belzutifan in ccRCC. The approval is based on the LITESPARK-011 trial showing improved progression-free survival compared to cabozantinib, though overall survival benefit was not statistically significant; safety monitoring for anemia, hypoxia, hypertension, and cardiac dysfunction is advised.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 24 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
You gain a new market if you develop treatments for ccRCC after immunotherapy progression. This approval opens a commercial door for therapies pairing novel hypoxia-targeting drugs with VEGF inhibitors but demands careful toxicity management.
◆ Coverage
8 sources · first reported 24 Sep 2026 · latest 28 Sep 2026
◆ Related on Wire
◆ Topics